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What if we knew how metabolites were transported
inside and outside of cells? As a metabolic engineer,
one could make cell factories export the product into the
fermentation broth, likely improving the process perfor-
mance and lowering the cost of downstream processing.
If the product secreted from the cell, it would not inhibit
its biosynthesis, it would be less toxic, and it would less
likely be degraded. One could also prevent the leakage
of pathway intermediates and improve the precursor sup-
ply in a speciﬁc cellular compartment.
Despite these apparent advantages, strain develop-
ment programs often overlook metabolites transport. As
an illustrative example, one can search for the occur-
rence of words ‘transport’ or ‘export’ among the papers
published in Metabolic Engineering journal over the past
ﬁve years, to discover that these words occur in only 6%
of the papers (PubMed). One might wonder why? There
may be at least three good reasons. First, there is a dis-
agreement in the scientiﬁc community as to whether
small metabolites are mainly transported through trans-
porter proteins or if they also diffuse directly through the
lipid bilayer (Sugano et al., 2010; Kell et al., 2011). Sec-
ond, the methods for analysing transporter activity are
technically complicated and require investment in spe-
cialized equipment and the necessary expertise
(Brouwer et al., 2013). It is in contrast to biochemical
methods for enzyme activity, where many assays can be
implemented on a simple spectrophotometer. Third (and
consequently), as the knowledge on transport remains
limited, so are our abilities to modulate the transport pro-
cesses. Hence, there are relatively few success stories
on how such knowledge can be applied for strain
development. These factors create a vicious circle, where
limited knowledge and complicated methodologies dis-
courage the scientists to enter this research area, and so
it remains uncharted.
An eukaryotic model organism yeast Saccharomyces
cerevisiae has 341 putative transporters predicted from its
genome sequence (http://www.membranetransport.org).
For the majority of the annotated transporters, the function
was assigned based on sequence similarity and was not
experimentally validated. A recent yeast genome-scale
metabolic model iIN800 contains ca. 220 unique transport
reactions, which are physiologically essential or have
been experimentally validated to occur in the cells (Noo-
kaew et al., 2008). For less than half of these transport
reactions, a possible responsible transporter is assigned.
For the export of non-native compounds, the responsible
transporters are largely unknown.
Nevertheless, several successful transport engineering
cases inspire conﬁdence that this is a promising research
direction. The widely used ﬂavour enhancer monosodium
glutamate (MSG) has been produced by fermentation of
coryneform bacteria since 1957 (Sano, 2009). The original
process was based on wild isolates, which were capable of
secreting several grams per litre of L-glutamate under the
right cultivation conditions. It was ﬁrst recently discovered
that the efﬁcient secretion was due to a mechanosensitive
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channel, which released osmoprotectants, such as gluta-
mate, in response to changes in membrane tension (Naka-
mura et al., 2007). Corynebacterium glutamicum is
perhaps the best example of a cell factory, where the trans-
porters have been successfully engineered to enable efﬁ-
cient production of multiple amino acids and derived
products (Perez-Garcıa and Wendisch, 2018).
Another illustrative example is the engineering of
dicarboxylic acid secretion by yeasts. While yeast S.
cerevisiae is an attractive host for production of car-
boxylic acids due to its excellent tolerance to low pH,
the transporters for commercially attractive endogenous
(e.g., succinic, fumaric, malic) and exogenous (e.g., adi-
pic, cis,cis-muconic, 3-hydroxypropionic) acids are
unknown. Evolutionary, it cannot be expected that S.
cerevisiae would naturally be efﬁcient at secreting
endogenous organic acids because of the high cellular
demand for these metabolites. The same applies for
exogenous metabolites; there is meagre chance that
yeast would encode an efﬁcient transporter for these
metabolites as it neither produces nor utilizes these
metabolites in nature. In contrast, natural producers of
metabolites are likely to encode highly active efﬂux
transporters for these compounds.
Overexpression of transporter-encoding gene MAE1
from malate-utilizing yeast Schizosaccharomyces pombe
has dramatically improved the secretion of succinic and
malic acids in S. cerevisiae and some other yeasts (Hara
et al., 2017). We recently found that MAE1 most likely
belongs to the family of slow anion channels (SLAC1) and
not to proton- or sodium-coupled transporters. The trans-
porter thus operates with minimal energy use (our unpub-
lished results). In general, energy usage of transporters
should be taken into account when engineering cell facto-
ries; there seems to be an overall evolutionary trend
towards energetically less costly transport that we
described in (Darbani, 2018).
As the advantages of addressing the transport issue
become more apparent, the transporter research area
will grow and mature. New in vitro and in vivo methods
will be developed for studying transporter speciﬁcity and
kinetics; the throughput of these methodologies will be
scaled up. We are currently building a whole trans-
portome library of model eukaryote Saccharomyces
cerevisiae for screening in Xenopus expression system
and via solid surface membrane methodology (Nour-
Eldin et al., 2012; Bazzone et al., 2017).
In a few years, it will be possible to screen and iden-
tify exporters and importers of any desired metabolic
product. This knowledge will enable engineering of the
transport of metabolites, both in between the cellular
compartments and outside the cell.
Transporter studies are essential not only for the meta-
bolic engineering ﬁeld but also for drug development.
Drug transport may cause drug failure in clinical trials
when the drug is poorly taken up in the target tissue/or-
gan or is accumulated in non-target organs. Multidisci-
plinary ongoing research efforts on deorphanizing the
human transportome (e.g., https://re-solute.eu/) will con-
tribute to the development of methods for transporter
analysis and will improve the drug development pipeline.
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